Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ALLO-501A |
Trade Name | |
Synonyms | ALLO 501A|ALLO501A|Cemacabtagene ansegedleucel |
Drug Descriptions |
ALLO-501A comprises allogeneic T-lymphocytes engineered to remove the TCR alpha chain and CD52 and to express a chimeric antigen receptor (CAR) targeting CD19, which potentially induce lysis of CD19-expressing tumor cells (NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C172708 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ALLO-501A | ALLO-501A | 0 | 3 |